Phase 2 Brain Cancer Trial, Recruiting NCT06818331 Sponsor: The Third Affiliated hospital of Zhejiang Chinese Medical University Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06818331
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a high-grade brain tumour called WHO Grade IV glioma, as defined by a specific Chinese cancer treatment guideline.
  • People whose tumour has come back (recurred) after surgery, confirmed by a brain MRI scan.
  • People who have at least one tumour that can be measured on a brain scan, according to a standard set of assessment criteria.
  • People aged 18 to 70 years old (any gender).
  • People whose steroid medication (dexamethasone), if taken for brain swelling caused by the tumour, has been at a stable low dose (under 6 mg per day) in the 7 days before joining the trial (confirm with trial site for specific dosing rules).
  • People with a physical functioning score showing they are able to carry out at least limited self-care — a Karnofsky score of 40 or above, or a WHO performance score of 3 or below.
  • People whose blood counts, liver function, and kidney function fall within acceptable ranges on tests taken within 14 days before treatment (confirm with trial site for specific values).
  • People who are able to receive electroacupuncture treatment and are willing to attend consistently.
  • People who are fully conscious, able to feel and identify pain, and can communicate at a basic level.
  • People who have read and signed the informed consent form and are willing to take part voluntarily.

Who may not be able to join:

  • People experiencing seizures that cannot be controlled.
  • People who are currently enrolled in another clinical trial, or who finished another clinical trial less than one month ago.
  • People who have previously received treatment with paclitaxel or similar drugs.
  • People who have a severe allergic reaction to paclitaxel or similar substances.
  • People who are pregnant or breastfeeding.
  • People with conditions that affect thinking or memory, such as congenital dementia, or people with alcohol dependence, drug addiction, or misuse of mind-altering substances.
  • People who have a skin infection at the location where acupuncture needles would be placed.
  • People who have metal objects inside their body (such as implants or fragments).
  • People who are unable to have a contrast-enhanced brain MRI scan.
  • People with other serious medical conditions, mental health disorders, or abnormal test results that the trial doctor believes could increase health risks or affect the trial results.
  • People who are currently receiving other cancer treatments at the same time, such as chemotherapy, radiotherapy, targeted therapy, or immunotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-13858028101

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Registry
ClinicalTrials.gov
Start date
10 February 2025
Est. completion
24 February 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

4-month progression-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov